Aboukasm Amer, Reffi Anthony N, Drake Christopher L
Departments of Neurology and Sleep Medicine, Henry Ford Hospital, Detroit, Michigan.
Sleep Disorders & Research Center, Department of Sleep Medicine, Henry Ford Health System, Detroit, Michigan.
J Clin Sleep Med. 2025 May 1;21(5):753-756. doi: 10.5664/jcsm.11546.
Here we report our experience treating patients with narcolepsy using benzodiazepine receptor agonists, zolpidem, or eszopiclone taken at bedtime for both excessive daytime sleepiness and cataplexy.
We reviewed the medical records of 53 patients diagnosed with narcolepsy, between 2002 and 2023. Twenty-three patients, 8 with narcolepsy type 1 (NT1), 13 with narcolepsy type 2 (NT2), and 2 with secondary narcolepsy, were treated with benzodiazepine receptor agonists (20 zolpidem and 3 eszopiclone).
Seven out of 8 (88%) with narcolepsy type 1, 9 out of 13 (69%) with NT1, and 2 out of 2 (100%) with secondary narcolepsy, treated with benzodiazepine receptor agonists, had good to excellent self-reported response in their symptoms of excessive daytime sleepiness and/or cataplexy; 5 patients, 1 of whom with NT1, had marginal or no response. Three of the responding patients remained on zolpidem in monotherapy (ie, no stimulants).
The benzodiazepine receptor agonists drugs may be effective to manage several of the cardinal symptoms of narcolepsy, regardless of the narcolepsy type. Placebo controlled trials are needed to confirm our observations.
Aboukasm A, Reffi AN, Drake CL. Z hypnotics in the management of narcolepsy: a case series. . 2025;21(5):753-756.
在此我们报告使用苯二氮䓬受体激动剂、唑吡坦或艾司佐匹克隆在睡前治疗发作性睡病患者白天过度嗜睡和猝倒症状的经验。
我们回顾了2002年至2023年间53例被诊断为发作性睡病患者的病历。23例患者,其中8例为1型发作性睡病(NT1),13例为2型发作性睡病(NT2),2例为继发性发作性睡病,接受了苯二氮䓬受体激动剂治疗(20例使用唑吡坦,3例使用艾司佐匹克隆)。
接受苯二氮䓬受体激动剂治疗的8例1型发作性睡病患者中有7例(88%)、13例NT2患者中有9例(69%)以及2例继发性发作性睡病患者中有2例(100%),在白天过度嗜睡和/或猝倒症状方面自我报告的反应良好至极佳;5例患者,其中1例为NT1患者,反应微弱或无反应。3例有反应的患者继续接受唑吡坦单药治疗(即不使用兴奋剂)。
苯二氮䓬受体激动剂药物可能对控制发作性睡病的几种主要症状有效,无论发作性睡病的类型如何。需要进行安慰剂对照试验来证实我们的观察结果。
Aboukasm A, Reffi AN, Drake CL. Z hypnotics in the management of narcolepsy: a case series.. 2025;21(5):753 - 756.